Jakafi (ruxolitinib) - Incyte
Post-Transplant Lymphoproliferative Disorder After Successful Treatment of Graft-Versus Host Disease Following Liver Transplantation. (PubMed, Transplant Proc) - Oct 16, 2026 - "This is the first case of PTLD occurring after GVHD. Treatments such as extracorporeal photopheresis and ruxolitinib used in this case resulted in successful survival." 
Journal • Fibrosis • Gastroenterology • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Liver Cirrhosis • Lymphoma • Oncology • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/42881047
 
Ant Uzay; Can Boynukara; Cuyan Demirkesen; Özgür Özkayar
 
Oct 16, 2026
 
Prev Next